Expert perspectives on the diagnosis of vitiligo and considerations for improving provider awareness in dermatologist and community settings.
A comprehensive breakdown of the different classifications of vitiligo and how these may present clinically.
In this exclusive video interview, James Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the hype around the treatments.
Shared insight on the psychological and social impact of vitiligo, along with practical advice on how to communicate with and support patients.
Expert dermatologists Seemal Desai, MD, FAAD, and William Damsky, MD, PhD, provide an overview of vitiligo, as an autoimmune disorder, and its prevalence.
The potential of JAK inhibitors and other emerging medications could answer demand for more treatment options for these challenging skin conditions. Read down below.
Ruxolitinib meets primary and secondary endpoints in phase 3 TRuE-V clinical trial program.
Investigators reported that patients in the vitiligo group reported worse general health, and were willing to pay more than 40% of their income for a cure.
A recent study evaluated the efficacy of the patient reported outcome measure instrument Clinical Evolution-Vitiligo for scoring nonsegmental vitiligo.
A study in the Journal of the American Academy of Dermatology investigated the maintenance of results of ruxolitinib cream in patients with vitiligo.